ArticleWorld journal of nuclear medicine

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.

Majid Assadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.